![](https://www.ous-research.no/clinicalheartresearch/images/Group members/sigruha.jpg)
Sigrun Halvorsen
- Professor; MD, PhD
- +47 22 11 91 00
Mini-CV
Education (selected)
2015: Women´s Transforming Leadership course, University of Oxford/Saïd Business School, Oxford
2000: Board Certification in Cardiology
1997: Board Certification in Internal Medicine
1995: Dr. med. (doctor medicinae) in the field of Coagulation/Fibrinolysis, University of Oslo
1983: Cand. med. (M.D.) Faculty of Medicine, University of Oslo
Present positions
2013- present: Head of Department of Cardiology, OUS Ullevål, Oslo
2014- present: Professor of Cardiology, Institute of Clinical Medicine, University of Oslo
Awards, committees, memberships
- 2022-2024: Executive Board Member (Treasurer) of the ESC Association for Acute cardiovascular Care
- 2018-2022: Member of ESC Clinical Practice Guidelines Committee
- 2020-2022: Chair of the 2022 European Society of Cardiology (ESC) guideline on cardiovascular assessment and management of patients undergoing non-cardiac surgery
- Elected member of the Norwegian Academy of Science and Letters (DNVA) from 2022
- Board Member of ESC Association of Acute CardioVascular Care (ACVC) 2016-2022
- The research prize of the Norwegian Society of Cardiology, 2016
- Board Member of the ESC Working Group on Thrombosis 2012-2016
- Fellow of the European Society of Cardiology (ESC) from 2008
Other
- Co-authored over 240 articles (H-index 64)
- Project leader for the national RCT NORSCREEN (Norwegian Atrial Fibrillation Self Screening study)
- Executive steering committee member of the BETAMI trial (betablocker in myocardial infarction)
- National coordinator and/or principal investigator of large international multicenter trials: IMPROVE-IT, TRA-2P, APPRAISE-2, STREAM, ARISTOTLE, TECOS, REDUAL-PCI, ODYSSEY outcomes, AUGUSTUS, SELECT (studies on antiplatelet drugs, oral anticoagulants, fibrinolytics, lipid-lowering drugs, glucose-lowering drugs)
- 2022- present: Associate Editor, Eur Heart Journal of Acute Cardiovascular Care
- 2005- present: Editorial Board Member of Hjerteforum (Journal of the Norwegian Society of Cardiology).
Research Areas
- Antithrombotic therapy
- Acute myocardial infarction
- Atrial fibrillation
- Cardiovascular risk factors
- Coagulation/fibrinolysis
Publications 2024
Novel cardiac extracellular matrix biomarkers in STEMI: Associations with ischemic injury and long-term mortality
PLoS One, 19 (5), e0302732
DOI 10.1371/journal.pone.0302732, PubMed 38739599
Treatment patterns and adherence to lipid-lowering drugs during eight-year follow-up after a coronary heart disease event
Atherosclerosis, 393, 117550
DOI 10.1016/j.atherosclerosis.2024.117550, PubMed 38657552
Platelet activity, coagulation, and fibrinolysis in long-term users of anabolic-androgenic steroids compared to strength-trained athletes
Thromb Res, 238, 60-66
DOI 10.1016/j.thromres.2024.04.027, PubMed 38676967
Antithrombotic Strategies According to Age: Insights from the AUGUSTUS Trial
Am J Med (in press)
DOI 10.1016/j.amjmed.2024.06.001, PubMed 38876331
High Diagnostic Accuracy of Long-Term Electrocardiogram Interpretation by General Practitioners
Int J Telemed Appl, 2024, 6624344
DOI 10.1155/2024/6624344, PubMed 38425473
The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics
Eur Heart J Cardiovasc Pharmacother, 10 (3), 175-183
DOI 10.1093/ehjcvp/pvad093, PubMed 38017624
Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelines
Eur Heart J Acute Cardiovasc Care, 13 (1), 173-180
DOI 10.1093/ehjacc/zuad158, PubMed 38170562
Management of cardiac emergencies in women: a clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), the European Association of Percutaneous Cardiovascular Interventions (EAPCI), the Heart Failure Association (HFA), and the European Heart Rhythm Association (EHRA) of the ESC, and the ESC Working Group on Cardiovascular Pharmacotherapy
Eur Heart J Open, 4 (2), oeae011
DOI 10.1093/ehjopen/oeae011, PubMed 38628674
Screening for Atrial Fibrillation by Digital Health Technology in Older People in Homecare Settings: A Feasibility Trial
Int J Telemed Appl, 2024, 4080415
DOI 10.1155/2024/4080415, PubMed 38567031
Digital recruitment and compliance to treatment recommendations in the Norwegian Atrial Fibrillation self-screening pilot study
Eur Heart J Digit Health, 5 (3), 371-378
DOI 10.1093/ehjdh/ztae026, PubMed 38774377
Ventricular septal defect complicating acute myocardial infarction: diagnosis and management. A Clinical Consensus Statement of the Association for Acute CardioVascular Care (ACVC) of the ESC, the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC and the ESC Working Group on Cardiovascular Surgery
Eur Heart J, 45 (28), 2478-2492
DOI 10.1093/eurheartj/ehae363, PubMed 38888906
Comparative Safety and Effectiveness of Reduced Doses of Direct Acting Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
Am J Med, 137 (6), 520-528.e13
DOI 10.1016/j.amjmed.2024.02.005, PubMed 38387539
The REDUCE-AMI trial: an important step in cardiovascular drug de-prescription
Eur Heart J Acute Cardiovasc Care, 13 (4), 370-372
DOI 10.1093/ehjacc/zuae049, PubMed 38608152
Publications 2023
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis
Eur Heart J, 44 (4), 262-279
DOI 10.1093/eurheartj/ehac515, PubMed 36477865
European Society of Cardiology quality indicators for the cardiovascular pre-operative assessment and management of patients considered for non-cardiac surgery. Developed in collaboration with the European Society of Anaesthesiology and Intensive Care
Eur Heart J Qual Care Clin Outcomes, 9 (4), 331-341
DOI 10.1093/ehjqcco/qcac057, PubMed 36069905
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis
Nat Rev Cardiol, 20 (12), 830-844
DOI 10.1038/s41569-023-00901-2, PubMed 37474795
[2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC)]
G Ital Cardiol (Rome), 24 (1 Suppl 1), e1-e102
DOI 10.1714/3956.39326, PubMed 36645369
Extract from the 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery - Patient Blood Management
Blood Transfus, 22 (2), 122-129
DOI 10.2450/BloodTransfus.708, PubMed 38063786
Continue or discontinue aspirin before non-cardiac surgery?
Eur Heart J, 44 (26), 2410
DOI 10.1093/eurheartj/ehad246, PubMed 37155334
The roles of cardiac troponins before non-cardiac surgery
Eur Heart J, 44 (23), 2130-2131
DOI 10.1093/eurheartj/ehad226, PubMed 37098747
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab, 49 (2), 101418
DOI 10.1016/j.diabet.2022.101418, PubMed 36608816
Transvenous lead extractions in a single high-volume center over a 24-year period: High success rate and low complication rate
Heart Rhythm O2, 4 (4), 232-240
DOI 10.1016/j.hroo.2023.01.003, PubMed 37124554
The '10 commandments' for the 2022 European Society of Cardiology guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
Eur Heart J, 44 (5), 336-337
DOI 10.1093/eurheartj/ehac703, PubMed 36527277
The second strategic reperfusion early after myocardial infarction (STREAM-2) study
Eur Heart J Acute Cardiovasc Care, 12 (4), 219-221
DOI 10.1093/ehjacc/zuad024, PubMed 36895183
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC)
Eur Heart J Cardiovasc Pharmacother, 9 (3), 271-290
DOI 10.1093/ehjcvp/pvad016, PubMed 36869784
Fully digital self-screening for atrial fibrillation with patch electrocardiogram
Europace, 25 (5)
DOI 10.1093/europace/euad075, PubMed 36945146
[E. Sverre et al. respond]
Tidsskr Nor Laegeforen, 143 (3)
DOI 10.4045/tidsskr.23.0062, PubMed 36811436
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease
Eur Heart J Cardiovasc Pharmacother, 9 (5), 462-496
DOI 10.1093/ehjcvp/pvad032, PubMed 37120728
Geographical variation in persistence to oral anticoagulation therapy and clinical outcomes among patients with atrial fibrillation initiating therapy in Denmark, Sweden, Norway and Finland
Basic Clin Pharmacol Toxicol, 133 (2), 168-178
DOI 10.1111/bcpt.13902, PubMed 37230945
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
Cardiovasc Diabetol, 22 (1), 233
DOI 10.1186/s12933-023-01963-9, PubMed 37653496
Publications 2022
Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial
JAMA Cardiol, 7 (7), 682-689
DOI 10.1001/jamacardio.2022.1166, PubMed 35612866
Comparison of management and outcomes of ST-segment elevation myocardial infarction patients in Estonia, Hungary, Norway, and Sweden according to national ongoing registries
Eur Heart J Qual Care Clin Outcomes, 8 (3), 307-314
DOI 10.1093/ehjqcco/qcaa098, PubMed 33710273
Differences in characteristics, treatments and outcomes in patients with non-ST-elevation myocardial infarction: novel insights from four national European continuous real-world registries
Eur Heart J Qual Care Clin Outcomes, 8 (4), 429-436
DOI 10.1093/ehjqcco/qcab013, PubMed 33605415
Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs
Eur Heart J Open, 2 (6), oeac070
DOI 10.1093/ehjopen/oeac070, PubMed 36440353
Cardiovascular phenotype of long-term anabolic-androgenic steroid abusers compared with strength-trained athletes
Scand J Med Sci Sports, 32 (8), 1170-1181
DOI 10.1111/sms.14172, PubMed 35460300
Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Clinical Consensus Statement of the Acute CardioVascular Care Association (ACVC) and the ESC council of Cardio-Oncology-part 2: acute heart failure, acute myocardial diseases, acute venous thromboembolic diseases, and acute arrhythmias
Eur Heart J Acute Cardiovasc Care, 11 (11), 865-874
DOI 10.1093/ehjacc/zuac107, PubMed 36226746
[Checkpoint inhibitor-induced myocarditis]
Tidsskr Nor Laegeforen, 142 (18)
DOI 10.4045/tidsskr.21.0817, PubMed 36511752
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study
Eur Heart J Qual Care Clin Outcomes, 8 (5), 577-587
DOI 10.1093/ehjqcco/qcab048, PubMed 34244745
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
Eur Heart J, 43 (39), 3826-3924
DOI 10.1093/eurheartj/ehac270, PubMed 36017553
Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study
BMC Prim Care, 23 (1), 214
DOI 10.1186/s12875-022-01824-6, PubMed 36008778
Sex-related differences in the management and outcomes of patients hospitalized with ST-elevation myocardial infarction: a comparison within four European myocardial infarction registries
Eur Heart J Open, 2 (4), oeac042
DOI 10.1093/ehjopen/oeac042, PubMed 35919580
Cost-effectiveness of a rule-out algorithm of acute myocardial infarction in low-risk patients: emergency primary care versus hospital setting
BMC Health Serv Res, 22 (1), 1274
DOI 10.1186/s12913-022-08697-6, PubMed 36271364
Performance of the Novel Observation Group Criteria of the European Society of Cardiology (ESC) 0/1-Hour Algorithm in a Low-Risk Population
J Am Heart Assoc, 11 (7), e024927
DOI 10.1161/JAHA.121.024927, PubMed 35352564
Outcomes after delayed primary percutaneous coronary intervention vs. pharmaco-invasive strategy in ST-segment elevation myocardial infarction in Norway
Eur Heart J Cardiovasc Pharmacother, 8 (5), 442-451
DOI 10.1093/ehjcvp/pvab041, PubMed 34038535
Time trends in incidence, treatment, and outcome in acute myocardial infarction in Norway 2013-19
Eur Heart J Open, 2 (5), oeac052
DOI 10.1093/ehjopen/oeac052, PubMed 36071696
Time trends in adherence to guideline recommendations for anticoagulation therapy in patients with atrial fibrillation and myocardial infarction
Open Heart, 9 (1)
DOI 10.1136/openhrt-2021-001934, PubMed 35387862
Complement activation in association with clinical outcomes in ST-elevation myocardial infarction
Am Heart J Plus, 24, 100228
DOI 10.1016/j.ahjo.2022.100228, PubMed 38560636
Coagulation factors XI and XII as possible targets for anticoagulant therapy
Thromb Res, 214, 53-62
DOI 10.1016/j.thromres.2022.04.013, PubMed 35490644
Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Eur Heart J Acute Cardiovasc Care, 11 (12), 939-949
DOI 10.1093/ehjacc/zuac123, PubMed 36574353
Personalised cardiovascular disease prevention in the new guidelines
Tidsskr Nor Laegeforen, 142 (17)
DOI 10.4045/tidsskr.22.0508, PubMed 36416647
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis
Cardiovasc Res, 118 (6), 1385-1412
DOI 10.1093/cvr/cvab342, PubMed 34864874
The link between liver fat and cardiometabolic diseases is highlighted by genome-wide association study of MRI-derived measures of body composition
Commun Biol, 5 (1), 1271
DOI 10.1038/s42003-022-04237-4, PubMed 36402844
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)
Rev Esp Cardiol (Engl Ed), 75 (5), 429
DOI 10.1016/j.rec.2022.04.003, PubMed 35525570
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Eur J Prev Cardiol, 29 (1), 5-115
DOI 10.1093/eurjpc/zwab154, PubMed 34558602
[2021 ESC Guidelines on cardiovascular disease prevention in clinical practice]
G Ital Cardiol (Rome), 23 (6 Suppl 1), e3-e115
DOI 10.1714/3808.37926, PubMed 35708476
The new 2022 ESC Guidelines on Cardio-oncology and their impact on the Acute Cardiovascular Care Society
Eur Heart J Acute Cardiovasc Care, 11 (11), 844-849
DOI 10.1093/ehjacc/zuac129, PubMed 36205095
Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial
Open Heart, 9 (1)
DOI 10.1136/openhrt-2021-001892, PubMed 35172988
A nationwide registry study on heart failure in Norway from 2008 to 2018: variations in lookback period affect incidence estimates
BMC Cardiovasc Disord, 22 (1), 88
DOI 10.1186/s12872-022-02522-y, PubMed 35247979
Adherence and persistence to pharmacotherapy in patients with heart failure: a nationwide cohort study, 2014-2020
ESC Heart Fail, 10 (1), 405-415
DOI 10.1002/ehf2.14206, PubMed 36266969
Publications 2021
Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial
EBioMedicine, 70, 103511
DOI 10.1016/j.ebiom.2021.103511, PubMed 34329947
Music therapy in invasive cardiac procedures: Expanded perspective
BRIT. J. MUSIC THER., 13594575211039090
DOI 10.1177/13594575211039090
Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices
EuroIntervention, 17 (4), e274-e286
DOI 10.4244/EIJY21M05_01, PubMed 34057071
Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices
Eur Heart J Acute Cardiovasc Care, 10 (5), 570-583
DOI 10.1093/ehjacc/zuab015, PubMed 34057173
Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial
J Am Heart Assoc, 10 (24), e023143
DOI 10.1161/JAHA.121.023143, PubMed 34873913
Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases
Eur Heart J Acute Cardiovasc Care, 10 (8), 947-959
DOI 10.1093/ehjacc/zuab056, PubMed 34453829
Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Time Trends and Treatment Patterns
Clin Ther, 43 (7), 1179-1190.e3
DOI 10.1016/j.clinthera.2021.04.017, PubMed 34083030
Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Eur Heart J Cardiovasc Pharmacother, 7 (2), 125-140
DOI 10.1093/ehjcvp/pvaa009, PubMed 32049278
Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial
Circulation, 143 (12), 1215-1223
DOI 10.1161/CIRCULATIONAHA.120.051020, PubMed 33461308
Comparison of a single high-sensitivity cardiac troponin T measurement with the HEART score for rapid rule-out of acute myocardial infarction in a primary care emergency setting: a cohort study
BMJ Open, 11 (2), e046024
DOI 10.1136/bmjopen-2020-046024, PubMed 33627355
Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis
Eur Heart J Acute Cardiovasc Care, 10 (3), 343-355
DOI 10.1093/ehjacc/zuaa025, PubMed 33620437
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial
JACC Cardiovasc Interv, 14 (7), 768-780
DOI 10.1016/j.jcin.2021.02.022, PubMed 33826497
Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation
Heart, 108 (5), 345-352
DOI 10.1136/heartjnl-2020-318753, PubMed 33975877
Impact of Preinjury Antithrombotic Therapy on 30-Day Mortality in Older Patients Hospitalized With Traumatic Brain Injury (TBI)
Front Neurol, 12, 650695
DOI 10.3389/fneur.2021.650695, PubMed 34054695
Diagnostic Accuracy and Usability of the ECG247 Smart Heart Sensor Compared to Conventional Holter Technology
J Healthc Eng, 2021, 5230947
DOI 10.1155/2021/5230947, PubMed 34765102
2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group
Eur Heart J Acute Cardiovasc Care, 10 (2), 224-233
DOI 10.1093/ehjacc/zuaa037, PubMed 33550362
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Eur Heart J, 42 (34), 3227-3337
DOI 10.1093/eurheartj/ehab484, PubMed 34458905
Publications 2020
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
J Am Coll Cardiol, 75 (2), 133-144
DOI 10.1016/j.jacc.2019.10.057, PubMed 31948641
Music therapy as an adjunct in cardiac device lead extraction procedures: A randomized controlled trial
Appl Nurs Res, 56, 151376
DOI 10.1016/j.apnr.2020.151376, PubMed 33280783
Prevalence of genetically verified familial hypercholesterolemia among young (<45 years) Norwegian patients hospitalized with acute myocardial infarction
J Clin Lipidol, 14 (3), 339-345
DOI 10.1016/j.jacl.2020.04.002, PubMed 32418822
EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic
EuroIntervention, 16 (3), 233-246
DOI 10.4244/EIJY20M05_01, PubMed 32404302
EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic
Eur Heart J, 41 (19), 1839-1851
DOI 10.1093/eurheartj/ehaa381, PubMed 32405641
Incidence and prevalence of venous thromboembolism in Norway 2010-2017
Thromb Res, 195, 165-168
DOI 10.1016/j.thromres.2020.07.011, PubMed 32707359
Atrial fibrillation in acute heart failure: A position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology
Eur Heart J Acute Cardiovasc Care, 9 (4), 348-357
DOI 10.1177/2048872619894255, PubMed 31976747
Pre-hospital One-Hour Troponin in a Low-Prevalence Population of Acute Coronary Syndrome: OUT-ACS study
Open Heart, 7 (2)
DOI 10.1136/openhrt-2020-001296, PubMed 32719074
Pharmacy-dispensed drugs for secondary prevention after myocardial infarction
Tidsskr Nor Laegeforen, 140 (4)
DOI 10.4045/tidsskr.19.0416, PubMed 32192264
Incidence, risk factors and outcome of young patients with myocardial infarction
Heart, 106 (18), 1420-1426
DOI 10.1136/heartjnl-2019-316067, PubMed 32111640
Eivind Berge, MD, PhD, 1964-2020: Cardiologist Who Was Fighting Stroke
Stroke, 51 (5), 1353-1355
DOI 10.1161/STROKEAHA.120.029351, PubMed 32200755
Double-Stranded DNA and NETs Components in Relation to Clinical Outcome After ST-Elevation Myocardial Infarction
Sci Rep, 10 (1), 5007
DOI 10.1038/s41598-020-61971-7, PubMed 32193509
Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
Eur Heart J Cardiovasc Pharmacother, 6 (2), 75-85
DOI 10.1093/ehjcvp/pvz086, PubMed 31942972
The cardiac arrest centre for the treatment of sudden cardiac arrest due to presumed cardiac cause - aims, function and structure: Position paper of the Association for Acute CardioVascular Care of the European Society of Cardiology (AVCV), European Association of Percutaneous Coronary Interventions (EAPCI), European Heart Rhythm Association (EHRA), European Resuscitation Council (ERC), European Society for Emergency Medicine (EUSEM) and European Society of Intensive Care Medicine (ESICM)
Eur Heart J Acute Cardiovasc Care, 9 (4_suppl), S193-S202
DOI 10.1177/2048872620963492, PubMed 33327761
Worst lead ST deviation and resolution of ST elevation at one hour for prediction of myocardial salvage, infarct size, and microvascular obstruction in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention
Ann Noninvasive Electrocardiol, 25 (6), e12784
DOI 10.1111/anec.12784, PubMed 32592427
Diagnosis and risk stratification of chest pain patients in the emergency department: focus on acute coronary syndromes. A position paper of the Acute Cardiovascular Care Association
Eur Heart J Acute Cardiovasc Care, 9 (1), 76-89
DOI 10.1177/2048872619885346, PubMed 31958018
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Eur Heart J, 41 (44), 4245-4255
DOI 10.1093/eurheartj/ehaa649, PubMed 33051646
In memoriam Eivind Berge, MD, PhD, 1964-2020: cardiologist, trialist and hypertension/stroke researcher
J. Hypertens., 38 (6), 1199-1200
DOI 10.1097/HJH.0000000000002488
Incidence, prevalence, and mortality of heart failure: a nationwide registry study from 2013 to 2016
ESC Heart Fail, 7 (4), 1917-1926
DOI 10.1002/ehf2.12773, PubMed 32530563
Publications 2019
Invasive and antiplatelet treatment of patients with non-ST-segment elevation myocardial infarction: Understanding and addressing the global risk-treatment paradox
Clin Cardiol, 42 (10), 1028-1040
DOI 10.1002/clc.23232, PubMed 31317575
International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS
Am Heart J, 218, 57-65
DOI 10.1016/j.ahj.2019.08.016, PubMed 31707329
Experiences of informal caregivers after cardiac surgery: a systematic integrated review of qualitative and quantitative studies
BMJ Open, 9 (11), e032751
DOI 10.1136/bmjopen-2019-032751, PubMed 31719093
Facilitated music listening: Music therapy in an invasive cardiac procedure
BRIT. J. MUSIC THER., 33 (1), 27-38
DOI 10.1177/1359457519840131
"Doctor, Should I Keep Taking an Aspirin a Day?"
N Engl J Med, 380 (20), 1967-1970
DOI 10.1056/NEJMclde1903004, PubMed 31091380
Long-term cardiovascular morbidity following hyperemesis gravidarum: A Norwegian nationwide cohort study
PLoS One, 14 (6), e0218051
DOI 10.1371/journal.pone.0218051, PubMed 31188868
Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
Am Heart J, 221, 1-8
DOI 10.1016/j.ahj.2019.10.013, PubMed 31896036
Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups
BMC Med, 17 (1), 198
DOI 10.1186/s12916-019-1428-0, PubMed 31679516
Unsatisfactory risk factor control and high rate of new cardiovascular events in patients with myocardial infarction and prior coronary artery disease
BMC Cardiovasc Disord, 19 (1), 71
DOI 10.1186/s12872-019-1062-y, PubMed 30922234
Poor adherence to guideline recommendations among patients with atrial fibrillation and acute myocardial infarction
Eur J Prev Cardiol, 26 (13), 1373-1382
DOI 10.1177/2047487319841940, PubMed 30966816
Long-Term Survival after Invasive or Conservative Strategy in Elderly Patients with non-ST-Elevation Myocardial Infarction: A Prospective Cohort Study
Cardiology, 144 (3-4), 79-89
DOI 10.1159/000503442, PubMed 31689705
2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)
Europace, 21 (2), 192-193
DOI 10.1093/europace/euy174, PubMed 30052888
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial
Circulation, 140 (23), 1921-1932
DOI 10.1161/CIRCULATIONAHA.119.043308, PubMed 31557056
Publications 2018
Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial
Am Heart J, 208, 123-131
DOI 10.1016/j.ahj.2018.09.017, PubMed 30579505
The significance of ST-elevation in aVL in anterolateral myocardial infarction: An assessment by cardiac magnetic resonance imaging
Ann Noninvasive Electrocardiol, 23 (6), e12580
DOI 10.1111/anec.12580, PubMed 29971868
Correlation of anteroseptal ST elevation with myocardial infarction territories through cardiovascular magnetic resonance imaging
J Electrocardiol, 51 (4), 563-568
DOI 10.1016/j.jelectrocard.2018.03.016, PubMed 29996989
Use of ticagrelor alongside fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Practical perspectives based on data from the TREAT study
Clin Cardiol, 41 (10), 1322-1327
DOI 10.1002/clc.23043, PubMed 30098028
Diagnosing heart failure with NT-proBNP point-of-care testing: lower costs and better outcomes. A decision analytic study
BJGP Open, 2 (3), bjgpopen18X101596
DOI 10.3399/bjgpopen18X101596, PubMed 30564729
Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
Heart, 105 (3), 235-242
DOI 10.1136/heartjnl-2018-313351, PubMed 30209126
Cardiovascular risk profile at the age of 40-45 in women with previous hyperemesis gravidarum or hypertensive disorders in pregnancy: A population-based study
Pregnancy Hypertens, 12, 129-135
DOI 10.1016/j.preghy.2018.04.013, PubMed 29858105
Markers of Thrombin Generation Are Associated With Long-Term Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction
Clin Appl Thromb Hemost, 24 (7), 1088-1094
DOI 10.1177/1076029618764847, PubMed 29695176
Integrating the results of the CULPRIT-SHOCK trial in the 2017 ESC ST-elevation myocardial infarction guidelines: viewpoint of the task force
Eur Heart J, 39 (48), 4239-4242
DOI 10.1093/eurheartj/ehy294, PubMed 29850788
[2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.]
Kardiol Pol, 76 (2), 229-313
DOI 10.5603/KP.2018.0041, PubMed 29457615
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)
Eur Heart J, 39 (2), 119-177
DOI 10.1093/eurheartj/ehx393, PubMed 28886621
Correlation of ST changes in leads V4-V6 to area of ischemia by CMR in inferior STEMI
Scand Cardiovasc J, 52 (4), 189-195
DOI 10.1080/14017431.2018.1458145, PubMed 29595340
Cardiac Magnetic Resonance Evaluation of the Extent of Myocardial Injury in Patients with Inferior ST Elevation Myocardial Infarction and Concomitant ST Depression in Leads V1-V3: Analysis from the MITOCARE Study
Cardiology, 140 (3), 178-185
DOI 10.1159/000491745, PubMed 30099440
Design of the GutHeart-targeting gut microbiota to treat heart failure-trial: a Phase II, randomized clinical trial
ESC Heart Fail, 5 (5), 977-984
DOI 10.1002/ehf2.12332, PubMed 30088346
BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study
Am Heart J, 208, 37-46
DOI 10.1016/j.ahj.2018.10.005, PubMed 30530121
Longitudinal left ventricular function is globally depressed within a week of STEMI
Clin Physiol Funct Imaging, 38 (6), 1029-1037
DOI 10.1111/cpf.12521, PubMed 29701310
Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial
J Am Heart Assoc, 7 (3)
DOI 10.1161/JAHA.117.007444, PubMed 29419390
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis
Eur Heart J, 39 (19), 1672-1686f
DOI 10.1093/eurheartj/ehy066, PubMed 29509886
New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
Open Heart, 5 (2), e000931
DOI 10.1136/openhrt-2018-000931, PubMed 30613418
Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial
Open Heart, 5 (2), e000908
DOI 10.1136/openhrt-2018-000908, PubMed 30487982
Publications 2017
Appropriateness of anteroseptal myocardial infarction nomenclature evaluated by late gadolinium enhancement cardiovascular magnetic resonance imaging
J Electrocardiol, 51 (2), 218-223
DOI 10.1016/j.jelectrocard.2017.09.013, PubMed 29103621
Editor's Choice - Acute Cardiovascular Care Association Position Paper on Intensive Cardiovascular Care Units: An update on their definition, structure, organisation and function
Eur Heart J Acute Cardiovasc Care, 7 (1), 80-95
DOI 10.1177/2048872617724269, PubMed 28816063
Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, prior to Primary Percutaneous Coronary Intervention, Does Not Affect the Levels of Pro-Inflammatory Cytokines or Acute-Phase Proteins
Cardiology, 138 (2), 122-132
DOI 10.1159/000475460, PubMed 28651249
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis
Eur Heart J, 38 (19), 1455-1462
DOI 10.1093/eurheartj/ehw454, PubMed 27789570
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
Rev Esp Cardiol (Engl Ed), 70 (12), 1082
DOI 10.1016/j.rec.2017.11.010, PubMed 29198432
Geographical differences in prescription of secondary preventive drug therapy after acute myocardial infarction in Norway
Eur Heart J Cardiovasc Pharmacother, 3 (3), 132-133
DOI 10.1093/ehjcvp/pvx008, PubMed 28444199
Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial
Am Heart J, 197, 133-141
DOI 10.1016/j.ahj.2017.11.005, PubMed 29447773
Long-term survival in patients with acute myocardial infarction and out-of-hospital cardiac arrest: A prospective cohort study
Resuscitation, 122, 41-47
DOI 10.1016/j.resuscitation.2017.11.047, PubMed 29155294
Gender differences in all-cause, cardiovascular and cancer mortality during long-term follow-up after acute myocardial infarction; a prospective cohort study
BMC Cardiovasc Disord, 17 (1), 75
DOI 10.1186/s12872-017-0508-3, PubMed 28288586
Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease
Eur J Prev Cardiol, 24 (3_suppl), 61-70
DOI 10.1177/2047487317707854, PubMed 28618904
MMP-9 and Its Regulators TIMP-1 and EMMPRIN in Patients with Acute ST-Elevation Myocardial Infarction: A NORDISTEMI Substudy
Cardiology, 139 (1), 17-24
DOI 10.1159/000481684, PubMed 29141241
Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin)
Circulation, 136 (13), 1193-1203
DOI 10.1161/CIRCULATIONAHA.117.027252, PubMed 28626088
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis
J Am Coll Cardiol, 70 (14), 1760-1776
DOI 10.1016/j.jacc.2017.08.037, PubMed 28958334
Evaluation of circulating levels of CCN2/connective tissue growth factor in patients with ST-elevation myocardial infarction
Sci Rep, 7 (1), 11945
DOI 10.1038/s41598-017-12372-w, PubMed 28931920
Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis
Am Heart J, 193, 46-54
DOI 10.1016/j.ahj.2017.07.015, PubMed 29129254
Publications 2016
Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial
JAMA Cardiol, 1 (6), 673-81
DOI 10.1001/jamacardio.2016.1829, PubMed 27463942
Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction
Heart, 102 (7), 527-33
DOI 10.1136/heartjnl-2015-308075, PubMed 26783237
Monocyte-derived circulating microparticles (CD14+, CD14+/CD11b+ and CD14+/CD142+) are related to long-term prognosis for cardiovascular mortality in STEMI patients
Int J Cardiol, 227, 876-881
DOI 10.1016/j.ijcard.2016.11.302, PubMed 27915085
Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease
Thromb Haemost, 115 (4), 685-711
DOI 10.1160/TH15-09-0703, PubMed 26952877
Sample Size in Clinical Cardioprotection Trials Using Myocardial Salvage Index, Infarct Size, or Biochemical Markers as Endpoint
J Am Heart Assoc, 5 (3), e002708
DOI 10.1161/JAHA.115.002708, PubMed 26961520
Hyperemesis gravidarum and long-term mortality: a population-based cohort study
BJOG, 124 (7), 1080-1087
DOI 10.1111/1471-0528.14454, PubMed 27981734
Radial versus femoral access for percutaneous coronary intervention in ST-elevation myocardial infarction patients treated with fibrinolysis: Results from the randomized routine early invasive clinical trials
Cardiovasc Revasc Med, 17 (5), 295-301
DOI 10.1016/j.carrev.2016.03.008, PubMed 27116940
Female hearts A medical textbook about common heart disease
Tidsskr. Nor. Laegeforen., 136 (4), 333
DOI 10.4045/tidsskr.15.1299
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants
Eur Heart J Cardiovasc Pharmacother, 3 (1), 28-36
DOI 10.1093/ehjcvp/pvw031, PubMed 27680880
Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction
BMC Cardiovasc Disord, 16, 115
DOI 10.1186/s12872-016-0283-6, PubMed 27246583
Gender differences in the assessment and treatment of myocardial infarction
Tidsskr Nor Laegeforen, 136 (14-15), 1215-22
DOI 10.4045/tidsskr.16.0224, PubMed 27554562
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial
JAMA Cardiol, 1 (2), 126-35
DOI 10.1001/jamacardio.2016.0103, PubMed 27437883
Circulating Levels of IL-6 Receptor and gp130 and Long-Term Clinical Outcomes in ST-Elevation Myocardial Infarction
J Am Heart Assoc, 5 (6)
DOI 10.1161/JAHA.115.003014, PubMed 27412895
The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial
Eur Heart J, 37 (38), 2869-2878
DOI 10.1093/eurheartj/ehw124, PubMed 27071819
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study
J Am Heart Assoc, 5 (6)
DOI 10.1161/JAHA.116.003559, PubMed 28525886
Publications 2015
Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis
Heart, 101 (19), 1554-61
DOI 10.1136/heartjnl-2015-307815, PubMed 26175478
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis
Eur Heart J, 36 (46), 3238-49
DOI 10.1093/eurheartj/ehv304, PubMed 26163482
Myocardial perfusion grade predicts final infarct size and left ventricular function in patients with ST-elevation myocardial infarction treated with a pharmaco-invasive strategy (thrombolysis and early angioplasty)
EuroIntervention, 11 (5), 518-24
DOI 10.4244/EIJY15M04_02, PubMed 25868877
Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged
Heart, 101 (9), 692-8
DOI 10.1136/heartjnl-2014-306686, PubMed 25691510
Percutaneous coronary intervention in the patient on oral anticoagulation
Tidsskr. Nor. Laegeforen., 135 (1), 55
DOI 10.4045/tidsskr.14.1248
Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction
Thromb J, 13, 31
DOI 10.1186/s12959-015-0061-1, PubMed 26396552
Long-term survival in octogenarians and older patients with ST-elevation myocardial infarction in the era of primary angioplasty: A prospective cohort study
Eur Heart J Acute Cardiovasc Care, 5 (3), 243-52
DOI 10.1177/2048872615574706, PubMed 25753053
Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr
Am Heart J, 170 (3), 465-70
DOI 10.1016/j.ahj.2015.06.014, PubMed 26385029
Cardiac troponin elevations in acute non-coronary disease: Helpful or not?
Eur Heart J Acute Cardiovasc Care, 4 (5), 429-30
DOI 10.1177/2048872615573921, PubMed 25678669
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
J Am Heart Assoc, 4 (12)
DOI 10.1161/JAHA.115.002015, PubMed 26627878
Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction?
J Am Heart Assoc, 4 (8), e002049
DOI 10.1161/JAHA.115.002049, PubMed 26304934
Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS)
Europace, 17 (8), 1197-214
DOI 10.1093/europace/euv190, PubMed 26105732
Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial
Eur Heart J, 36 (46), 3268-75
DOI 10.1093/eurheartj/ehv447, PubMed 26371113
Publications 2014
Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results
Eur Heart J, 36 (2), 112-9
DOI 10.1093/eurheartj/ehu331, PubMed 25179768
Routine invasive management early after fibrinolysis: relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials
Am Heart J, 168 (5), 757-65
DOI 10.1016/j.ahj.2014.07.027, PubMed 25440805
Health-related quality of life after myocardial infarction, does choice of method make a difference?
Scand Cardiovasc J, 48 (4), 216-22
DOI 10.3109/14017431.2014.923581, PubMed 24828790
Prevalence of risk factors at presentation and early mortality in patients aged 80 years or older with ST-segment elevation myocardial infarction
Vasc Health Risk Manag, 10, 683-9
DOI 10.2147/VHRM.S72764, PubMed 25525366
Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis
J Am Coll Cardiol, 64 (3), 319-27
DOI 10.1016/j.jacc.2014.03.049, PubMed 25034070
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial
Eur Heart J, 35 (28), 1864-72
DOI 10.1093/eurheartj/ehu046, PubMed 24561548
Myocardial infarction in Norway in 2013
Tidsskr Nor Laegeforen, 134 (19), 1841-6
DOI 10.4045/tidsskr.14.0804, PubMed 25314984
Adaptation of trustworthy guidelines developed using the GRADE methodology: a novel five-step process
Chest, 146 (3), 727-734
DOI 10.1378/chest.13-2828, PubMed 25180723
Applying new strategies for the national adaptation, updating, and dissemination of trustworthy guidelines: results from the Norwegian adaptation of the Antithrombotic Therapy and the Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Chest, 146 (3), 735-761
DOI 10.1378/chest.13-2993, PubMed 25180724
[New guidelines for antithrombotic therapy and thromboprophylaxis]
Tidsskr Nor Laegeforen, 134 (9), 921-2
DOI 10.4045/tidsskr.13.1582, PubMed 24828713
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)
Eur Heart J, 35 (45), 3155-79
DOI 10.1093/eurheartj/ehu298, PubMed 25154388
Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST-segment elevation myocardial infarction: a patient-level analysis of the randomized early routine invasive clinical trials
JACC Cardiovasc Interv, 8 (1 Pt B), 166-174
DOI 10.1016/j.jcin.2014.09.005, PubMed 25616922
Networks for improving care in patients with acute coronary syndrome: A framework
Acute Card Care, 16 (2), 41-8
DOI 10.3109/17482941.2014.881502, PubMed 24654609
ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up
Circulation, 130 (14), 1139-45
DOI 10.1161/CIRCULATIONAHA.114.009570, PubMed 25161043
[Antithrombotic treatment in atrial fibrillation and cardiovascular disease]
Tidsskr Nor Laegeforen, 134 (9), 923
DOI 10.4045/tidsskr.13.1618, PubMed 24828714
Publications 2013
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction
N Engl J Med, 368 (15), 1379-87
DOI 10.1056/NEJMoa1301092, PubMed 23473396
Fibrinolytic treatment of ST-elevation myocardial infarction. Update 2014
Hamostaseologie, 34 (1), 47-53
DOI 10.5482/HAMO-13-07-0040, PubMed 24085113
IL-6 signalling in patients with acute ST-elevation myocardial infarction
Results Immunol, 4, 8-13
DOI 10.1016/j.rinim.2013.11.002, PubMed 24707455
Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?
Eur Heart J, 34 (22), 1630-5
DOI 10.1093/eurheartj/eht110, PubMed 23554440
Publications 2012
Ethnicity and acute myocardial infarction: risk profile at presentation, access to hospital management, and outcome in Norway
Vasc Health Risk Manag, 8, 505-15
DOI 10.2147/VHRM.S33627, PubMed 22956878
STEMI treatment in areas remote from primary PCI centres
EuroIntervention, 8 Suppl P, P44-50
DOI 10.4244/EIJV8SPA8, PubMed 22917789
Inflammatory and thrombotic markers in patients with ST-elevation myocardial infarction treated with thrombolysis and early PCI: a NORDISTEMI substudy
Thromb Res, 130 (3), 495-500
DOI 10.1016/j.thromres.2012.04.016, PubMed 22607887
The German Centre for Cardiovascular Research
Eur Heart J, 33 (9), 1033-36,1036a
PubMed 22893891
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
Eur Heart J, 33 (20), 2569-619
DOI 10.1093/eurheartj/ehs215, PubMed 22922416
Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease--a cost-effectiveness analysis
BMC Cardiovasc Disord, 12, 26
DOI 10.1186/1471-2261-12-26, PubMed 22475076
Publications 2011
Health and cost consequences of early versus late invasive strategy after thrombolysis for acute myocardial infarction
Eur J Cardiovasc Prev Rehabil, 18 (5), 717-23
DOI 10.1177/1741826711398425, PubMed 21450598
The role of beta-blockers in the treatment of chronic heart failure
Trends Pharmacol Sci, 32 (4), 206-12
DOI 10.1016/j.tips.2011.01.006, PubMed 21376403
Amino-terminal pro-B-type natriuretic peptide (NT-proBNP) levels 3 months after myocardial infarction are more strongly associated with magnetic resonance-determined ejection fraction than NTproBNP levels in the acute phase
J Card Fail, 17 (6), 479-86
DOI 10.1016/j.cardfail.2011.02.006, PubMed 21624736
Assessment of left ventricular function in ST-elevation myocardial infarction by global longitudinal strain: a comparison with ejection fraction, infarct size, and wall motion score index measured by non-invasive imaging modalities
Eur J Echocardiogr, 12 (9), 678-83
DOI 10.1093/ejechocard/jer113, PubMed 21810829
Publications 2010
Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis
Eur Heart J, 31 (17), 2156-69
DOI 10.1093/eurheartj/ehq204, PubMed 20601393
The association between metabolic syndrome and infarct size in patients with acute myocardial infarction
Scand J Clin Lab Invest, 70 (4), 287-93
DOI 10.3109/00365513.2010.481819, PubMed 20429699
The role of fibrinolysis in the era of primary percutaneous coronary intervention
Thromb Haemost, 105 (3), 390-5
DOI 10.1160/TH10-08-0513, PubMed 21136014
Left ventricular function in acute myocardial infarction treated with thrombolysis followed by early versus late invasive strategy
Am Heart J, 160 (1), 73-9
DOI 10.1016/j.ahj.2010.04.011, PubMed 20598975
Assessment of left ventricular function with magnetic resonance imaging vs. echocardiography, contrast echocardiography, and single-photon emission computed tomography in patients with recent ST-elevation myocardial infarction
Eur J Echocardiogr, 11 (9), 793-800
DOI 10.1093/ejechocard/jeq069, PubMed 20525984
Spotlight: Sigrun Halvorsen, MD, PhD, FESC
Circulation, 121 (2), F10-F11
Publications 2009
Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction)
J Am Coll Cardiol, 55 (2), 102-10
DOI 10.1016/j.jacc.2009.08.007, PubMed 19747792
Troponin T concentration 3 days after acute ST-elevation myocardial infarction predicts infarct size and cardiac function at 3 months
Cardiology, 113 (3), 207-12
DOI 10.1159/000201991, PubMed 19218804
Gender differences in management and outcome of acute myocardial infarctions treated in 2006-2007
Cardiology, 114 (2), 83-8
DOI 10.1159/000216582, PubMed 19420934
[Symptoms and diagnosis of coronary heart disease in women]
Tidsskr Nor Laegeforen, 129 (18), 1853-7
DOI 10.4045/tidsskr.09.0115, PubMed 19844276
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]
G Ital Cardiol (Rome), 10 (7), 450-89
PubMed 19761103
Publications 2008
[Coronary disease in young women]
Tidsskr Nor Laegeforen, 128 (2), 188
PubMed 18240395
Publications 2007
The NORwegian study on DIstrict treatment of ST-elevation myocardial infarction (NORDISTEMI)
Scand Cardiovasc J, 41 (1), 32-8
DOI 10.1080/14017430601153472, PubMed 17365975
The role of statins in patients with arterial hypertension
Arch. Med. Sci., 3 (4A), S97-S101
Publications 2006
Myocardial perfusion in ST-elevation myocardial infarction treated successfully with primary angioplasty
Scand Cardiovasc J, 40 (2), 96-104
DOI 10.1080/14017430600628144, PubMed 16608779
Publications 2005
Cost-effectiveness of primary percutaneous coronary intervention versus thrombolytic therapy for acute myocardial infarction
Scand Cardiovasc J, 39 (5), 276-85
DOI 10.1080/14017430510035988, PubMed 16269397
Publications 2004
Kostnader og nytte ved å erstatte trombolyse med PCI ved akutt hjerteinfarkt: en analyse basert på CORINOR-modellen (Coronary Intervention Model Norway)
In Rapport, Kunnskapssenteret, Oslo, nr 3/2004, 36 s.
BIBSYS 041576403, ISBN 82-8121-003-6
[Acute myocardial infarction in a young man who had been using androgenic anabolic steroids]
Tidsskr Nor Laegeforen, 124 (2), 170-2
PubMed 14743229
Akutt hjerteinfarkt hos ung mann som brukte androgene anabole steroider
In Tidsskrift for Den norske legeforening, Foreningen, Oslo, 124(2004)nr. 2, S. 170-172
BIBSYS 040141470
Measurements of heart motion using accelerometers
P ANN INT IEEE EMBS, 26, 2049-2051
Measurements of heart motion using accelerometers
IEEE SENSOR, 1353-1354
DOI 10.1109/ICSENS.2004.1426434
The viscosity of fibrinogen subfractions and of EDTA denatured fibrinogen do not differ from that of native fibrinogen
Thromb Res, 113 (1), 51-6
DOI 10.1016/j.thromres.2004.01.010, PubMed 15081565
[Reduction of myocardial infarction size after primary percutaneous coronary intervention]
Tidsskr Nor Laegeforen, 124 (10), 1387-9
PubMed 15195177
Publications 2003
[Primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction?]
Tidsskr Nor Laegeforen, 123 (2), 152-5
PubMed 12607494
Primær angioplastikk eller trombolytisk behandling ved akutt hjerteinfarkt?
[Den Norske lægeforening], [Oslo], S. 152-155.
BIBSYS 041421612
Publications 2002
[Left ventricular function and infarction size after primary angioplasty for acute myocardial infarction]
Tidsskr Nor Laegeforen, 122 (24), 2350-4
PubMed 12448247
Influence of freeze-drying on the clotting properties of fibrinogen in plasma
Thromb Res, 105 (6), 499-502
DOI 10.1016/s0049-3848(02)00057-9, PubMed 12091049
Publications 2001
Left ventricular function and infarct size 20 months after primary angioplasty for acute myocardial infarction
Scand Cardiovasc J, 35 (6), 379-84
DOI 10.1080/14017430152754862, PubMed 11837517
[Diagnoses and increased levels of troponin T among discharged patients]
Tidsskr Nor Laegeforen, 121 (26), 3041-5
PubMed 11757436
Publications 2000
Discrepancy between fibrinogen concentrations determined by clotting rate and clottability assays during the acute-phase reaction
Thromb Res, 100 (5), 397-403
DOI 10.1016/s0049-3848(00)00344-3, PubMed 11150581
Publications 1999
Severe liver failure in exertional heat stroke
Scand J Gastroenterol, 34 (8), 824-7
DOI 10.1080/003655299750025778, PubMed 10499485
[Fibrinogen as a cardiovascular risk factor--marker or causal factor?]
Tidsskr Nor Laegeforen, 119 (19), 2829-32
PubMed 10494205
Prosthetic heart valve thrombosis during dicloxacillin therapy
Scand Cardiovasc J, 33 (6), 366-8
DOI 10.1080/14017439950141443, PubMed 10622550
Publications 1998
Ethanol treatment in ethylene glycol poisoned patients
Vet Hum Toxicol, 40 (4), 225-8
PubMed 9682410
Publications 1996
D-dimers are degraded by human neutrophil elastase
Thromb Res, 82 (2), 177-86
DOI 10.1016/0049-3848(96)00064-3, PubMed 9163071
Activation of coagulation and deep vein thrombosis after bone marrow harvesting and insertion of a Hickman-catheter in ABMT patients with malignant lymphoma
Bone Marrow Transplant, 17 (4), 577-81
PubMed 8722358
Publications 1995
Impaired clot lysis in the presence of human neutrophil elastase
Thromb Res, 80 (2), 153-9
DOI 10.1016/0049-3848(95)00161-j, PubMed 8588192
Publications 1994
Degradation of the alpha-chain of fibrin by human neutrophil elastase reduces the stimulating effect of fibrin on plasminogen activation
Thromb Res, 75 (3), 307-17
DOI 10.1016/0049-3848(94)90241-0, PubMed 7992241
Impaired coagulation of fibrinogen due to digestion of the C-terminal end of the A alpha-chain by human neutrophil elastase
Thromb Res, 73 (1), 61-8
DOI 10.1016/0049-3848(94)90054-x, PubMed 8178314
Publications 1993
Thrombin treated plasma employed as a standard for determination of soluble fibrin
Thromb Res, 72 (4), 305-13
DOI 10.1016/0049-3848(93)90139-f, PubMed 8303670
The stimulatory capacity of soluble fibrin prepared from high and low molecular weight fibrinogen on plasminogen activation
Blood Coagul Fibrinolysis, 4 (1), 133-7
DOI 10.1097/00001721-199304010-00023, PubMed 8457641
Publications 1992
Does Lp(a) lipoprotein inhibit the fibrinolytic system?
Thromb Res, 68 (3), 223-32
DOI 10.1016/0049-3848(92)90080-t, PubMed 1471070
Publications 1991
The stimulatory effect of soluble fibrin on plasminogen activation by tissue plasminogen activator as studied by the Coa-set Fibrin Monomer test
Thromb Res, 61 (4), 453-61
DOI 10.1016/0049-3848(91)90659-k, PubMed 1905851
Comparison of methods for detecting soluble fibrin in plasma from patients with venous thromboembolism
Thromb Res, 61 (3), 341-8
DOI 10.1016/0049-3848(91)90112-a, PubMed 2028450
Publications 1990
Comparison of methods for detecting soluble fibrin in plasma. An in vitro study
Thromb Res, 57 (4), 489-97
DOI 10.1016/0049-3848(90)90066-l, PubMed 2326770